Gaining Stereoselectivity in Asymmetric Synthesis - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

Gaining Stereoselectivity in Asymmetric Synthesis
Researchers use inorganic catalysts as an alternative to biocatalysts in the selective conversion of sugars to produce chiral building blocks.

Pharmaceutical Technology
Volume 37, Issue 2

Other advances in chiral chemistry

Researchers at the Department of Applied Chemistry, the Faculty of Science, at the Tokyo University of Science and the Japanese Foundation Center for Cancer Research developed a method for the total synthesis of AMF-26, an antitumor agent that disrputs the Golgi system by inhibiting ADP-ribosylation factor 1 activation (2). A key part of the synthesis was the construction of the chiral linear precursor by the asymmetric aldol reaction followed by a computer-assisted predictive stereoselective intramolecular Diels–Alder reaction (2).

Researchers also recently reported on what they classified as the first organocatalytic asymmetric synthesis of 3,3-disubstituted oxindoles featuring two heteroatoms at the C3 position by employing the highly enantioselective amination of 3-arylthiooxindoles or 3-alkoxyoxindoles using DBAD (3). The work showed that 3-thiooxindoles and 3-alkoxyoxindoles were reactive nucleophiles for the development of catalytic asymmetric reactions (3). In other news, researchers describe their work involving a catalytic asymmetric double (1,3)-dipolar cycloaddition reaction. They reported that by using a chiral silver catalyst, enantioenriched pyrrolizidines can be prepared in one flask from inexpensive, commercially available starting materials. The pyrrolizidine products contain a variety of substitution patterns and as many as six stereogenic centers (4).

In the area of biocatalysis, researchers at the School of Chemical and Biomolecular Engineering, Georgia Institute of Technology, Petit Institute of Bioengineering and Bioscience and Merck & Co., successfully altered a leucine dehydrogenase through several rounds of protein engineering to an enantioselective amine dehydrogenase (5). Instead of the wild-type a-keto acid, the new amine dehydrogenase accepts the analogous ketone, methyl isobutyl ketone, which corresponds to exchange of the carboxy group by a methyl group to produce chiral (R)-1,3-dimethylbutylamine (5).

Other catalytic approaches

Antibody drug conjugates remain a niche, but strong area of investment.
In synthesizing pharmaceutical intermediates or APIs, broad advances in catalysis can be helpful. The research group of Professor Petri Pihko at the Department of Chemistry and the NanoScience Center of the University of Jyväskylä at the Academy of Finland recently resolved two problems in chemical catalysis, according to a Dec. 20, 2012 press release.

In the first project, the researchers designed an intramolecularly assisted catalyst for the synthesis of beta-amino acids. Previously published catalysts work only with aromatic side chains in the imines, but the new catalyst designed at the University of Jyväskylä does not have this limitation, according to the release. The method may be applied in the synthesis of beta-amino acids, which are important building blocks. For the understanding of the catalytic mechanism and design of the catalyst, the researchers collaborated with the research groups of Professor Imre Pápai at the Hungarian Academy of Sciences for computational studies, and Academy Professor Kari Rissanen at the University of Jyväskylä for X-ray characterization of catalysts.

In a second project, the researchers identified new mechanism for the amine-catalyzed Michael addition reaction between aldehydes and nitroalkenes. The new model proposed by the Pihko and Pápai groups includes a new species, a six-membered ring, as the key on-cycle intermediate that is protonated in the rate-determining step. The work is a combination of computational and experimental studies that complement each other in understanding the reaction mechanism. Specifically, the researchers used dihydrooxazine oxides, which are stable intermediates that are protonated directly, without the intermediacy of the zwitterions, in organocatalytic Michael additions of aldehydes and nitroalkenes. Protonation of these species explains the role of the acid co-catalyst in these reactions, and the observed stereochemistry when the reaction is conducted with a-alkylnitroalkenes (6).

BINOL and its derivatives are widely used classes of ligands in asymmetric synthesis, such as in Diels–Alder reactions, carbonyl addition, and reductions (7). Researchers at the University of Texas, Austin have developed a bifunctional catalyst derived from BINOL for producing highly enantioselective bromolactonizations of unsaturated carboxylic acids (8, 9). Specifically, the catalyst promoted highly enantioselective bromolactonizations of 4- and 5-aryl-4-pentenoic acids, but it also catalyzed the highly enantioselective bromolactonizations of 5-alkyl-4(Z)-pentenoic acids. The researchers assert that these reactions represent the first catalytic bromolactonizations of alkyl-substituted olefinic acids that proceeded by means of 5-exo mode cyclizations to give lactones in which new carbon–bromine bonds are formed at a stereogenic center with high enantioselectivity. The researchers also reported on what they say is the first catalytic desymmetrization of a prochiral dienoic acid by enantioselective bromolactonization (8, 9).


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
New Congress to Tackle Health Reform, Biomedical Innovation, Tax Policy
Combination Products Challenge Biopharma Manufacturers
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
Source: Pharmaceutical Technology,
Click here